Systemic therapy
toxicity, intolerable adverse events, death
DISEASE PROGRESSION
Eligible patients received sintilimab (Innovent [Suzhou] Biopharmaceutical Co., Ltd.) 200 mg intravenously once on Day 1 and subsequently every 3 weeks, plus anlotinib (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) 12 mg orally on Days 1–14 of the 21‐day treatment cycle, until disease progression or death, unacceptable toxicity, withdrawal of consent, or for a maximum of 24 months (35 cycles) of sintilimab. No other antitumor therapy was allowed before disease progression. For sintilimab, no dose adjustment was allowed. For anlotinib, the investigator could reduce the dose to 10 mg, 8 mg, or permanently discontinue treatment according to drug‐related toxicity. Patients with intolerable adverse events (AEs) that led to a delay or discontinuation of one study drug continued treatment with the other drug.